日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Androgen Receptor Drives Polyamine Synthesis, Creating a Vulnerability for Prostate Cancer.

雄激素受体驱动多胺合成,从而增加患前列腺癌的风险。

Kumar Rajendra, Jonnatan Sheila, Sanin David E, Vakkala Varsha, Kadam Anoushka, Kumar Shivani, Rosen D Marc, Dalrymple Susan L, Zhao Liang, Foley Jackson R, Holbert Cassandra E, Nwafor Ashley, Kittane Srushti, Penner Elizabeth, Apostolova Petya, Warner Samuel, Dang Chi V, Toska Eneda, Thompson Elizabeth A, Isaacs John T, De Marzo Angelo M, Brennen W Nathaniel, Pearce Erika L, Stewart Tracy Murray, Casero Robert A Jr, Denmeade Samuel R, Sena Laura A

The Histone Methyltransferase KMT2D Is a Critical Mediator of Lineage Plasticity and Therapeutic Response in Castration-Resistant Prostate Cancer.

组蛋白甲基转移酶 KMT2D 是去势抵抗性前列腺癌谱系可塑性和治疗反应的关键介质。

Kittane Srushti, Ladewig Erik, Li Taibo, Love Jillian R, Blawski Ryan, Gao Yangzhenyu, Arruabarrena-Aristorena Amaia, Zhao Peihua, Dalrymple Susan L, Liu Huayang, Guo Xinyu, Sallaku Mirna, Kelkar Nachiket, Garcia-Martinez Liliana, Carmona Sanz Javier, Chen Wanlu, Stoudmann Candice, Baldino Laura, Razavi-Mohseni Milad, Kalemi Ingrid, Beer Michael A, Castel Pau, Brennen W Nathaniel, Scaltriti Maurizio, Morey Lluis, Cocco Emiliano, Ji Hongkai, Chan Ho Man, Battle Alexis, Leslie Christina S, Karthaus Wouter R, Toska Eneda

Dasatinib resensitizes BRAF/MEK inhibitor efficacy in patient-derived xenografts from patients with progression on BRAF/MEK inhibitor treatment

达沙替尼可使BRAF/MEK抑制剂在BRAF/MEK抑制剂治疗后病情进展的患者来源的异种移植模型中重新发挥疗效。

Rebecca, Vito W; Xiao, Min; Kossenkov, Andrew; Godok, Tetiana; Brown, Gregory Schuyler; Fingerman, Dylan; Alicea, Gretchen M; Wei, Meihan; Ji, Hongkai; Portuallo, Marie; Bravo, Jeremy; Elad, Vissy; Chen, Yeqing; Toska, Eneda; Fane, Mitchell E; Couts, Kasey L; Villanueva, Jessie; Nathanson, Katherine; Arun, Keerthana M; Warrier, Govind; Yin, Xiangfan; Ding, Jianyi; Liu, Qin; Goyal, Yogesh; Gopal, Y N Vashisht; Davies, Michael A; Herlyn, Meenhard

Inhibition of NR2F2 restores hormone therapy response to endocrine refractory breast cancers

抑制NR2F2可恢复内分泌难治性乳腺癌的激素治疗反应

Cai, Yanyan; Zhao, Peihua; Wu, Fan; Zhao, Huiyong; Shao, Hong; Marra, Antonio; Patel, Payal; O'Connell, Elizabeth; Fink, Emma; Miele, Matthew M; Li, Zhuoning; De Stanchina, Elisa; Cocco, Emiliano; Razavi, Pedram; Toska, Eneda; Fanning, Sean W; Xu, Guotai; Sablina, Anna A; Scaltriti, Maurizio; Chandarlapaty, Sarat

TFE3 fusion oncoprotein condensates drive transcriptional reprogramming and cancer progression in translocation renal cell carcinoma.

TFE3 融合癌蛋白凝聚体驱动易位性肾细胞癌的转录重编程和癌症进展

So Choon Leng, Lee Ye Jin, Vokshi Bujamin H, Chen Wanlu, Huang Binglin, De Sousa Emily, Gao Yangzhenyu, Portuallo Marie Elena, Begum Sumaiya, Jagirdar Kasturee, Linehan W Marston, Rebecca Vito W, Ji Hongkai, Toska Eneda, Cai Danfeng

Responsiveness of different MET tumour alterations to type I and type II MET inhibitors.

不同MET肿瘤改变对I型和II型MET抑制剂的反应性

Murciano-Goroff Yonina R, Foglizzo Valentina, Chang Jason, Rekhtman Natasha, Sisk Ann Elizabeth, Gibson Jamie, Judka Lia, Clemens Kristen, Roa Paola, Ahmed Shaza Sayed, Bremer Nicole V, Binaco Courtney Lynn, Muzungu Sherifah Kemigisha, Rodriguez Estelamari, Merrill Madeline, Sgroe Erica, Repetto Matteo, Stadler Zsofia K, Berger Michael F, Yu Helena A, Toska Eneda, Kannan Srinivasaraghavan, Verma Chandra S, Drilon Alexander, Cocco Emiliano

Zurletrectinib is a next-generation TRK inhibitor with strong intracranial activity against NTRK fusion-positive tumours with on-target resistance to first-generation agents

Zurletrectinib 是一种新一代 TRK 抑制剂,对具有靶向耐药性的 NTRK 融合阳性肿瘤具有强大的颅内活性。

Roa, Paola; Foglizzo, Valentina; Harada, Guilherme; Repetto, Matteo; Kulick, Amanda; de Stanchina, Elisa; de Marchena, Michelle; Auwardt, Supipi; Sayed Ahmed, Shaza; Bremer, Nicole Virginia; Yang, Soo-Ryum; Feng, Yangbo; Zhou, Chao; Kong, Norman; Liang, Ruixia; Xu, Haipeng; Zhang, Bin; Bardelli, Alberto; Toska, Eneda; Ventura, Andrea; Drilon, Alexander; Cocco, Emiliano

PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer

PI3K/AKT/mTOR信号转导通路及其在癌症中的靶向治疗

Glaviano, Antonino; Foo, Aaron S C; Lam, Hiu Y; Yap, Kenneth C H; Jacot, William; Jones, Robert H; Eng, Huiyan; Nair, Madhumathy G; Makvandi, Pooyan; Geoerger, Birgit; Kulke, Matthew H; Baird, Richard D; Prabhu, Jyothi S; Carbone, Daniela; Pecoraro, Camilla; Teh, Daniel B L; Sethi, Gautam; Cavalieri, Vincenzo; Lin, Kevin H; Javidi-Sharifi, Nathalie R; Toska, Eneda; Davids, Matthew S; Brown, Jennifer R; Diana, Patrizia; Stebbing, Justin; Fruman, David A; Kumar, Alan P

A Unique FOXA1-Associated Chromatin State Dictates Therapeutic Resistance in Lobular Breast Cancer

一种独特的FOXA1相关染色质状态决定了小叶性乳腺癌的治疗耐药性

Blawski, Ryan; Toska, Eneda

Epigenetic Mechanisms Influencing Therapeutic Response in Breast Cancer

影响乳腺癌治疗反应的表观遗传机制

Arruabarrena-Aristorena, Amaia; Toska, Eneda